Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Summary

This is a multicenter, randomized, double-blind, parallel-group, 2 treatment group, repeated dose study to compare the PK, efficacy, safety, and immunogenicity of AVT32-DRL\_PB (proposed Keytruda® biosimilar) versus Keytruda (pembrolizumab) when administered as monotherapy in participants with fully resected Stage IIB/C or Stage III melanoma requiring adjuvant treatment with pembrolizumab. Eligible participants will be randomized in a 1:1 ratio to the AVT32-DRL\_PB or Keytruda treatment group and stratified by sex (female versus male) and body weight category (≤75 kg versus \>75 kg). Study treatments will be administered every 3 weeks (Q3W) as an intravenous (IV) infusion over 30 minutes (1 administration Q3W is 1 treatment cycle). The administered pembrolizumab dose will be 200 mg Q3W for both treatment groups.

Eligibility

Inclusion Criteria:

* Participants (male/female) ≥18 years of age at the time of signing the ICF.
* Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at the time of enrollment.
* Participants with Stage IIB, IIC, or III histologically confirmed cutaneous melanoma

Exclusion Criteria:

* Have had a solid organ transplant or bone marrow (stem cell) transplant that used donor stem cells (allogenic).
* Has received prior systemic anticancer therapy for melanoma including investigational agents.
* Participants with a history of mucosal or uveal melanoma, even if diagnosis and treatment were completed \>5 years ago.

Conditions2

Interventions2

Related trials

• A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC — Qilu Pharmaceutical Co., Ltd.
• European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] — University of Leipzig
• IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer — Innovent Biologics (Suzhou) Co. Ltd.
• Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer — Maria Sklodowska-Curie National Research Institute of Oncology
• Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab — Strand Therapeutics Inc.
• Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab — Strand Therapeutics Inc.
• Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients — Philogen S.p.A.
• A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) — National Cancer Institute (NCI)

Browse More Trials